Akums Drugs & Pharmaceuticals has announced the launch of the world’s first Lasmiditan dispersible tablets, marking an important step forward in the treatment of acute migraine.
The DCGI-approved formulation introduces a patient-friendly approach to migraine management, designed to provide faster and more convenient relief during sudden migraine attacks.
Headache disorders remain one of the most common neurological conditions globally, yet they continue to be under-recognised and under-treated. Migraine, in particular, is a debilitating neurovascular disorder characterised by recurrent episodes of throbbing, often one-sided headaches accompanied by symptoms such as nausea, vomiting, sensitivity to light, and sensitivity to sound.
Akums’ new dispersible tablet formulation is designed to address some of the most common challenges patients face during migraine attacks.
The formulation is engineered with a dual disintegration mechanism of swelling and effervescence for rapid dispersion and faster therapeutic action during acute migraine.
In addition, Akums has developed advanced taste-masking technology to overcome the intensely bitter taste of Lasmiditan, improving palatability and making the treatment easier for patients to take during acute attacks. Together, these features contribute to better patient compliance at a time when quick relief is critical.
Lasmiditan belongs to the ‘ditans’ class of anti-migraine drugs and acts as a highly selective serotonin 5-HT1F receptor agonist. With a binding affinity that is more than 440 times higher for the 5-HT1F receptor than for 5-HT1B/1D receptors, the drug works directly on sensory neurons associated with migraine pathways.
Because of this targeted mechanism, Lasmiditan is often referred to as a neurally active anti-migraine agent. It is indicated for the acute treatment of migraine with or without aura in adults and is not intended for preventive therapy.
